Asian Pacific Journal of Cancer Prevention

  • 제15권1호
  • /
  • Pages.179-184
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Curcumin and its Analogues (PGV-0 and PGV-1) Enhance Sensitivity of Resistant MCF-7 Cells to Doxorubicin through Inhibition of HER2 and NF-kB Activation

  • Meiyanto, Edy (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada) ;
  • Putri, Dyaningtyas Dewi Pamungkas (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada) ;
  • Susidarti, Ratna Asmah (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada) ;
  • Murwanti, Retno (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada) ;
  • Sardjiman, Sardjiman (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada) ;
  • Fitriasari, Aditya (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada) ;
  • Husnaa, Ulfatul (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada) ;
  • Purnomo, Hari (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada) ;
  • Kawaichi, Masashi (Lab Of Gene Function, School of Biosciences, Nara Institute of Science and Technology)
  • 발행 : 2014.01.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Chemoresistance of breast cancer to doxorubicin is mediated mainly through activation of NF-kB and over expression of HER2. Curcumin and its analogues (PGV-0 and PGV-1) exert cytotoxic effects on T47D breast cancer cells. Suppression of NF-kB activation is suggested to contribute to this activity. The present study aimed to explore the effects of curcumin, PGV-0, and PGV-1 singly and in combination with doxorubicin on MCF-7/Dox cells featuring over-expression of HER2. In MTT assays, curcumin, PGV-0, and PGV-1 showed cytotoxicity effects against MCF-7/Dox with IC50 values of $80{\mu}M$, $21{\mu}M$, and $82{\mu}M$ respectively. These compounds increased MCF-7/Dox sensitivity to doxorubicin. Cell cycle distribution analysis exhibited that the combination of curcumin and its analogues with Dox increased sub G-1 cell populations. Curcumin and PGV-1 but not PGV-0 decreased localization of p65 into the nucleus induced by Dox, indicating that activation of NF-kB was inhibited. Molecular docking of curcumin, PGV-0, and PGV-1 demonstrated high affinity to HER2 at ATP binding site. This interaction were directly comparable with those of ATP and lapatinib. These findings suggested that curcumin, PGV-0 and PGV-1 enhance the Dox cytotoxicity to MCF-7 cells through inhibition of HER2 activity and NF-kB activation.

키워드

참고문헌

  1. Aggarwal BB, Kumar A, Bharti AC (2003). Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res, 23, 363-98.
  2. Byun SS, Kim SW, Choi H, Lee C, Lee E (2005). Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU Int, 95, 1086-90. https://doi.org/10.1111/j.1464-410X.2005.05472.x
  3. Claeson P, Tuchinda P, Revtrakul V (1994). Naturally occuring 1,7-diarylheptanoids, J Indian Chem Soc, 71, 509-21.
  4. Da'i M, Jenie UA, Supardjan AM, Kawaichi M, Meiyanto E (2007). T47D cells arrested at G2M and hyperploidy formation induced by a curcumin analogue, PGV-1, Indon. J Biotechnol, 12, 1005-12.
  5. Da'i M, Supardjan AM, Meiyanto E, Jenie UA (2007). Isomers geometric and cytotoxic effect curcumin analogue PGV-0 and PGV-1 on T47D cells. Indonesian J Pharm, 18, 40-7.
  6. Hanahan D, Weinberg RA (2011). The hallmark of cancer: The next generation. Cell, 100, 57-70.
  7. Kiguchi K, Carbajal S, Chan K (2001). Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res, 61, 6971-6.
  8. Kuttan PR, Bhanumathy P, Nirmala K, George GC (1985). Potential anticancer activity of turmeric (Curcuma longa), Cancer Lett, 29, 197-202. https://doi.org/10.1016/0304-3835(85)90159-4
  9. Lutomsky J, Kedzia B, Debska W (1974). Effect of an alcohol extract and of active ingredients from Curcuma longa on bacteria and fungi. Planta Medica, 26, 9-19. https://doi.org/10.1055/s-0028-1097963
  10. Mazumder A, Neamati N, Sunder S, et al (1997). Curcumin analogues with altered potencies against HIV-1 integrase as probes for biochemical mechanism of drug action. J Med Chem, 40, 3057-63. https://doi.org/10.1021/jm970190x
  11. Meiyanto E, Supardjan, Da'i M, Agustina D (2006). Antiproliferative effect of pentagamavunon-0 on T47D breast cancer cells. Med J Yarsi, 14, 11-5.
  12. Meiyanto E, Supardjan, Da'i M, Agustina D (2007). Pentagamavunon-0 induces Apoptosis on T47D breast cancer cell line through caspase-3 activation. Med J Yarsi, 15, 75-9.
  13. Nasiri M, Zarghami N, Koshki KN, et al (2013). Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. Asian Pac J Cancer Prev, 14, 3449-53. https://doi.org/10.7314/APJCP.2013.14.6.3449
  14. Putri DDP, Sarmoko, Febriansah R, et al (2012). MCF-7 resistant doxorubicin are characterized by lamellipodia, strong adhesion on substrate and pgp overexpression. Indo J Can Chemoprev, 2, 304-8.
  15. Ramprasad C, Sirrsi M (1957). Curcuma longa and bile secretion-quantitative changes in the bile constituents induced by sodium curcuminate. J Sci Industry Res, 16, 108-10.
  16. Sardjiman (2000). Synthesis of Some New Series of Curcumin Analogues, Anti-Oxidative, Anti-Inflammatory, Anti-Bacterial Acitivities and Qualitative Structure-Activity-Relationship, Disertation, Gadjah Mada University.
  17. Shankar TNB, Murthy VS (1979). Effect of turmeric (curcuma longa) fractions on the growth of some intestinal and pathogenic bacteria in vitro. Indian J Exp Biol, 17, 1363-6.
  18. Sharma SC, Mukhtar H, Sharma SK, Krishnamurti CR (1972). Lipid peroxide formation in experimental inflammation. Biochem Pharmacol, 21, 1210-4. https://doi.org/10.1016/0006-2952(72)90118-9
  19. Shishodia S, Majumdar S, Banerjee S, Aggarwal BB (2003). Ursolic acid inhibits nuclear factor-${\kappa}$B${\alpha}$ kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res, 63, 4375-83.
  20. Srimal RC, Dhawan BN (1973). Pharmacology of diferuloyl methane (curcumin) a non steroid anti-inflamatory agent. J Pharm Pharmac, 25, 447-52. https://doi.org/10.1111/j.2042-7158.1973.tb09131.x
  21. Vadlamudi R, Mandal M, Adam L, et al (1999). Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene, 18, 305-14. https://doi.org/10.1038/sj.onc.1202307
  22. Vora T, de Azambuja E, Awada A, Piccart M (2009). Novel therapeutics in breast cancer-looking to the future. Update Cancer Therapeutics, 3, 189-205. https://doi.org/10.1016/j.uct.2009.07.001

피인용 문헌

  1. Systemic Analysis on Risk Factors for Breast Cancer Related Lymphedema vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6535
  2. Targeting epidermal growth factor receptors and downstream signaling pathways in cancer by phytochemicals vol.10, pp.3, 2015, https://doi.org/10.1007/s11523-014-0339-4
  3. Curcumin enhances the antitumor effect of ABT-737 via activation of the ROS-ASK1-JNK pathway in hepatocellular carcinoma cells vol.13, pp.2, 2015, https://doi.org/10.3892/mmr.2015.4715
  4. Synergistically Improved Anti-tumor Efficacy by Co-delivery Doxorubicin and Curcumin Polymeric Micelles vol.15, pp.9, 2015, https://doi.org/10.1002/mabi.201500043
  5. Luteolin Attenuates Doxorubicin-Induced Cytotoxicity to MCF-7 Human Breast Cancer Cells vol.38, pp.5, 2015, https://doi.org/10.1248/bpb.b14-00780
  6. Curcumin inhibits LPA-induced invasion by attenuating RhoA/ROCK/MMPs pathway in MCF7 breast cancer cells vol.16, pp.1, 2016, https://doi.org/10.1007/s10238-015-0336-7
  7. Validated LC-MS/MS method for simultaneous determination of doxorubicin and curcumin in polymeric micelles in subcellular compartments of MCF-7/Adr cells by protein precipitation-ultrasonic breaking method vol.31, pp.6, 2016, https://doi.org/10.1002/bmc.3892
  8. Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment vol.6, pp.1, 2016, https://doi.org/10.1038/srep34397
  9. Cardioprotective Effect of Phenytoin on Doxorubicin-induced Cardiac Toxicity in a Rat Model vol.67, pp.3, 2016, https://doi.org/10.1097/FJC.0000000000000339
  10. Her-2 expression regulated by downregulation of miR-9 and which affects chemotherapeutic effect in breast cancer vol.24, pp.5, 2017, https://doi.org/10.1038/cgt.2014.82
  11. Extract Decrease Proliferation and Cell Viability of Soft-Tissue Sarcoma Cells: An In Vitro Analysis of Eight Cell Lines Using Real-Time Monitoring and Colorimetric Assays vol.69, pp.2, 2017, https://doi.org/10.1080/01635581.2017.1263349
  12. Furanodiene Induces Extrinsic and Intrinsic Apoptosis in Doxorubicin-Resistant MCF-7 Breast Cancer Cells via NF-κB-Independent Mechanism vol.8, pp.1663-9812, 2017, https://doi.org/10.3389/fphar.2017.00648
  13. Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas vol.10, pp.4, 2018, https://doi.org/10.3390/cancers10040089
  14. Effect of tween 80 on nanoparticle preparation of modified chitosan for targeted delivery of combination doxorubicin and curcumin analogue vol.311, pp.1757-899X, 2018, https://doi.org/10.1088/1757-899X/311/1/012024
  15. Cancer chemoprevention and therapy using chinese herbal medicine vol.20, pp.1, 2018, https://doi.org/10.1186/s12575-017-0066-1
  16. Preclinical Study of Novel Curcumin Analogue SSC-5 Using Orthotopic Tumor Xenograft Model for Esophageal Squamous Cell Carcinoma vol.50, pp.4, 2018, https://doi.org/10.4143/crt.2017.353